U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C40H56O3
Molecular Weight 584.8708
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 9
Charge 0

SHOW SMILES / InChI
Structure of CAPSANTHIN

SMILES

CC(\C=C\C=C(C)\C=C\C(=O)[C@]1(C)C[C@@H](O)CC1(C)C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)C[C@@H](O)CC2(C)C

InChI

InChIKey=VYIRVAXUEZSDNC-RDJLEWNRSA-N
InChI=1S/C40H56O3/c1-29(17-13-19-31(3)21-23-36-33(5)25-34(41)26-38(36,6)7)15-11-12-16-30(2)18-14-20-32(4)22-24-37(43)40(10)28-35(42)27-39(40,8)9/h11-24,34-35,41-42H,25-28H2,1-10H3/b12-11+,17-13+,18-14+,23-21+,24-22+,29-15+,30-16+,31-19+,32-20+/t34-,35+,40+/m1/s1

HIDE SMILES / InChI

Description

Capsanthin, the red xanthophyll pigment, is used as a food additive approved by the European Union (EU) under the name as E160c. The common names for E160c are paprika extract, capsanthin or capsorubin. Capsanthin shows potent anti-adipogenic, lipolytic and fatty acid burning activities due to its potent adrenoceptor-beta2-agonistic activity. It was revealed, that capsanthin was not a thermogenic substance that is why it may be a good candidate for the development of new bioactive agent effective as a new anti-obese or insulin sensitivity enhancing substance.

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
Supplementing capsanthin-rich paprika juice for 1 wk (equivalent to three doses of 5.4 micromol capsanthin/d; 16.2 micromol/d), the level of capsanthin reached a plateau (0.10-0.12 micromol/L) between d 2 and 7 and was not detectable by d 16.
Route of Administration: Oral
In Vitro Use Guide
Capsanthin Inhibits adipogenesis in 3T3-L1 preadipocytes. During adipogenesis in 3T3-L1 preadipocytes, capsanthin (10 uM) inhibited adipogenesis (IC₅₀; 2.5 μM) and also showed lipolytic activity in differentiated adipocytes from the preadipocytes (ED₅₀; 872 nM). It was found, that the pharmacological activity of capsanthin on adipogenesis in 3T3-L1 was mainly due to its adrenoceptor-β₂-agonistic activity